BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by lacking expression of estrogen receptor and progesterone receptor as well as absence of human epidermal growth factor receptor 2 overexpression and is an aggressive clinical phenotype. PATIENTS AND METHODS: We report the case of a 33-year-old woman who has been treated using a targeted approach for TNBC and developed a malignant melanoma metastasis without any primary. RESULTS AND CONCLUSION: Using targeted therapies, tumors can be treated much more effectively, but up to now, we do not know much about potential adverse reactions. Due to the targeted therapy, tumors may be pressurized for transformation. We call for further investigations to rule out the potential risks of targeted therapy in TNBC. This is the first report of a potential transforming of one tumor entity to another by a targeted therapy.
BACKGROUND: Triple-negative breast cancer (TNBC) is characterized by lacking expression of estrogen receptor and progesterone receptor as well as absence of humanepidermal growth factor receptor 2 overexpression and is an aggressive clinical phenotype. PATIENTS AND METHODS: We report the case of a 33-year-old woman who has been treated using a targeted approach for TNBC and developed a malignant melanoma metastasis without any primary. RESULTS AND CONCLUSION: Using targeted therapies, tumors can be treated much more effectively, but up to now, we do not know much about potential adverse reactions. Due to the targeted therapy, tumors may be pressurized for transformation. We call for further investigations to rule out the potential risks of targeted therapy in TNBC. This is the first report of a potential transforming of one tumor entity to another by a targeted therapy.
Authors: Lene Mellemkjaer; Søren Friis; Jørgen H Olsen; Ghislaine Scélo; Kari Hemminki; Elizabeth Tracey; Aage Andersen; David H Brewster; Eero Pukkala; Mary L McBride; Erich V Kliewer; Jon M Tonita; Chia Kee-Seng; Vera Pompe-Kirn; Carmen Martos; Jon G Jonasson; Paolo Boffetta; Paul Brennan Journal: Int J Cancer Date: 2006-05-01 Impact factor: 7.396
Authors: Helena R Chang; John Glaspy; Mary Ann Allison; Frederic C Kass; Robert Elashoff; Debra U Chung; Jeffrey Gornbein Journal: Cancer Date: 2010-09-15 Impact factor: 6.860
Authors: Fabrice Andre; Bastien Job; Philippe Dessen; Attila Tordai; Stefan Michiels; Cornelia Liedtke; Catherine Richon; Kai Yan; Bailang Wang; Gilles Vassal; Suzette Delaloge; Gabriel N Hortobagyi; W Fraser Symmans; Vladimir Lazar; Lajos Pusztai Journal: Clin Cancer Res Date: 2009-01-15 Impact factor: 12.531
Authors: David Loesch; Nicholas Robert; Lina Asmar; Mary Ann Gregurich; Mark O'Rourke; Shaker Dakhil; Edwin Cox Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544